CWM
BIIB icon

Catamount Wealth Management’s Biogen BIIB Stock Holding History

Catamount Wealth Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$24K Buy
+100
New +$31.5K 0.01% 106

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catamount Wealth Management's BIIB Position: Q1 2019 in Review

Catamount Wealth Management opened a new position in Biogen (BIIB) in Q1 2019: 100 shares worth $24K. The stake represents 0.01% of the portfolio and ranks #106 among its holdings.

1,084 funds tracked by Wall St. Rank hold BIIB as of Q1 2019.

  • Catamount Wealth Management held 100 shares of Biogen worth $24K as of Q1 2019.
  • Biogen was a new Catamount Wealth Management position in Q1 2019.
  • Biogen made up 0.01% of Catamount Wealth Management's portfolio in Q1 2019, its #106 holding.
  • 1,084 funds tracked by Wall St. Rank held Biogen as of Q1 2019.

Based on Catamount Wealth Management's 13F filing for Q1 2019, filed 3 May 2019.